340B Reform: US House Bills Mark The End Of The Beginning
Energy & Commerce Health Subcommittee releases several discussion drafts at hearing on 340B drug discount program reform as the debate seems poised to move into the next phase.
You may also be interested in...
US 340B Discount Restrictions By Pharma: HRSA Will Continue To ‘Walk The Walk’ In Opposition
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
Pharma Manufacturers Mobilize Against 340B Discounts At Contract Pharmacies
AstraZeneca, Merck & Co., Sanofi and Novartis join Eli Lilly in taking action. But providers in the US federal discount program are pushing back.
Lilly Bars Contract Pharmacies From 340B Discounts Despite HRSA Guidance
Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.